Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Intern Med ; 62(6): 939-943, 2023 Mar 15.
Article in English | MEDLINE | ID: mdl-35989268

ABSTRACT

Purulent pericarditis is an infection of the pericardial cavity that produces purulent fluid and is commonly caused by Streptococcus pneumoniae. We herein report an autopsy case that is unique in two respects: the patient had pneumococcal bacteremia from a skin and soft tissue infection associated with acupuncture as well as purulent pericarditis from pneumococcal bacteremia. This case suggests that bloodstream infection should be included in the differential diagnosis on observing pneumococcal pericarditis. Furthermore, it is necessary to recognize that S. pneumoniae may be the organism responsible for skin and soft tissue infections caused by trauma in immunosuppressed patients.


Subject(s)
Acupuncture Therapy , Bacteremia , Pericarditis , Pneumococcal Infections , Humans , Autopsy , Pericarditis/complications , Streptococcus pneumoniae , Pneumococcal Infections/complications , Pericardium , Bacteremia/complications
2.
CNS Neurosci Ther ; 24(10): 930-939, 2018 10.
Article in English | MEDLINE | ID: mdl-29524300

ABSTRACT

AIMS: Streptococcus pneumoniae infection in acute bacterial meningitis can lead to widespread brain damage and mortality. Inflammatory responses by immune cells in the brain are thought to determine the degree of brain injury. Yet, the mechanisms underlying host responses to pneumococcal meningitis are largely unknown. To explore host responses as a potential therapeutic target for preventing brain injury after pneumococcal meningitis. METHODS: We evaluated signaling mechanisms that minimize neuronal damage caused by pneumococcal infection; specifically, we assessed pathways related to neuronal survival after enhancing estrogen receptor-ß (ER-ß) expression using a natural therapeutic substance known as ginsenoside Rb1 and Rg3 enhanced ginseng. RESULTS: Tissue damage caused by bacterial infection was reduced in Rb1/Rg3-treated mice as a result of microglial activation and the inhibition of apoptosis. Furthermore, Rb1 upregulated the expression of brain-derived neurotrophic factor (BDNF) as well as anti-apoptotic factors including Bcl-2 and Bcl-xL. Using BV2 microglial cells in vitro, Rb1 treatment inhibited microglial apoptosis in a manner associated with JAK2/STAT5 phosphorylation. CONCLUSION: After S. pneumoniae infection in mice, particularly in female mice, Rb1-containing ginseng increased bacterial clearance and survival. These findings inform our understanding of the host immune response to pneumococcal meningitis.


Subject(s)
Brain Injuries/prevention & control , Estrogen Receptor beta/metabolism , Ginsenosides/therapeutic use , Microglia/metabolism , Neuroprotective Agents/therapeutic use , Sex Characteristics , Animals , Apoptosis/drug effects , Brain Injuries/etiology , Brain Injuries/pathology , Cell Line, Transformed , Disease Models, Animal , Estrogen Receptor beta/genetics , Female , Gene Expression Regulation/drug effects , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Pneumococcal Infections/complications , Pneumococcal Infections/drug therapy , Proto-Oncogene Proteins c-bcl-2/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Time Factors
3.
AIDS Patient Care STDS ; 30(10): 463-470, 2016 10.
Article in English | MEDLINE | ID: mdl-27749111

ABSTRACT

It is unclear whether HIV-infected individuals remain at higher risk of invasive pneumococcal disease (IPD) compared with HIV-uninfected individuals. We conducted a cohort study of HIV-infected and demographically matched HIV-uninfected adults within Kaiser Permanente Northern California during the period 1996-2011. We used Poisson models to obtain rate ratios (RRs) for incident IPD associated with HIV infection and other risk factors. Among 13,079 HIV-infected and 137,643 HIV-uninfected adults, the IPD rate per 100,000 person-years was 160 (n = 109 events) for HIV-infected and 8 (n = 75 events) for HIV-uninfected subjects, with an adjusted RR of 13.0 [95% confidence interval (CI): 9.1-18.7]. For HIV-infected individuals, IPD incidence per 100,000 person-years decreased by 71% during study follow-up, from 305 in 1996-1999 to 88 in 2010-2011 (p < 0.001), with an adjusted RR of 6.6 (95% CI: 2.7-16.1) compared with HIV-uninfected subjects in 2010-2011. Risk factors for IPD among HIV-infected individuals included black compared with white race/ethnicity, smoking, cancer, and higher HIV RNA levels. The 23-valent pneumococcal polysaccharide vaccination was not associated with a reduced risk of IPD in HIV-infected or HIV-uninfected individuals. Among HIV-infected IPD cases, the most common serotype was 19A (33%), and 59% of serotypes were covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Despite a dramatic decline in IPD incidence for HIV-infected adults since 1996, IPD rates were nearly sevenfold higher compared with HIV-uninfected adults in recent years, even after adjustment for risk factors. Timely antiretroviral therapy initiation, risk reduction strategies, and recent guidelines recommending PCV13 use may further reduce IPD incidence among HIV patients.


Subject(s)
Black People/statistics & numerical data , HIV Infections/complications , Pneumococcal Infections/complications , Pneumococcal Vaccines/therapeutic use , Adult , Black People/ethnology , California/epidemiology , Case-Control Studies , Cohort Studies , Female , HIV Infections/epidemiology , Humans , Incidence , Male , Pneumococcal Infections/epidemiology , Pneumococcal Vaccines/immunology , Risk Factors , Risk Reduction Behavior , Serogroup , Streptococcus pneumoniae , Vaccination , Vaccines, Conjugate/immunology , Vaccines, Conjugate/therapeutic use
4.
PLoS One ; 11(2): e0149104, 2016.
Article in English | MEDLINE | ID: mdl-26863135

ABSTRACT

INTRODUCTION: Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia among HIV-infected persons. As more countries with high HIV prevalence are implementing infant pneumococcal conjugate vaccine (PCV) programs, we aimed to describe the baseline clinical characteristics of adult invasive pneumococcal disease (IPD) in the pre-PCV era in South Africa in order to interpret potential indirect effects following vaccine use. METHODS: National, active, laboratory-based surveillance for IPD was conducted in South Africa from 1 January 2003 through 31 December 2008. At 25 enhanced surveillance (ES) hospital sites, clinical data, including HIV serostatus, were collected from IPD patients ≥ 5 years of age. We compared the clinical characteristics of individuals with IPD in those HIV-infected and -uninfected using multivariable analysis. PCV was introduced into the routine South African Expanded Program on Immunization (EPI) in 2009. RESULTS: In South Africa, from 2003-2008, 17 604 cases of IPD occurred amongst persons ≥ 5 years of age, with an average incidence of 7 cases per 100 000 person-years. Against a national HIV-prevalence of 18%, 89% (4190/4734) of IPD patients from ES sites were HIV-infected. IPD incidence in HIV-infected individuals is 43 times higher than in HIV-uninfected persons (52 per 100 000 vs. 1.2 per 100 000), with a peak in the HIV-infected elderly population of 237 per 100 000 persons. Most HIV-infected individuals presented with bacteremia (74%, 3 091/4 190). HIV-uninfected individuals were older; and had more chronic conditions (excluding HIV) than HIV-infected persons (39% (210/544) vs. 19% (790/4190), p<0.001). During the pre-PCV immunization era in South Africa, 71% of serotypes amongst HIV-infected persons were covered by PCV13 vs. 73% amongst HIV-uninfected persons, p = 0.4, OR 0.9 (CI 0.7-1.1). CONCLUSION: Seventy to eighty-five percent of adult IPD in the pre-PCV era were vaccine serotypes and 93% of cases had recognized risk factors (including HIV-infection) for pneumococcal vaccination. These data describe the epidemiology of IPD amongst HIV-infected and -uninfected adults during the pre-PCV era and provide a robust baseline to calculate the indirect effect of PCV in future studies.


Subject(s)
HIV Infections/complications , HIV Infections/epidemiology , Pneumococcal Infections/complications , Pneumococcal Infections/epidemiology , Pneumococcal Vaccines/therapeutic use , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Multivariate Analysis , Pneumococcal Vaccines/immunology , Prevalence , Risk Factors , Serogroup , South Africa/epidemiology , Streptococcus pneumoniae , Vaccination , Vaccines, Conjugate/immunology , Vaccines, Conjugate/therapeutic use , Young Adult
5.
Int J Pediatr Otorhinolaryngol ; 79(12): 2129-33, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26454530

ABSTRACT

OBJECTIVES: The emergence of antibiotic-resistant bacteria is a major cause of treatment failure in children with acute otitis media (AOM). This study aimed to analyze the types of bacterial strains in fluid isolated from the middle ear of children with AOM who did not respond to oral antibiotic treatment. We also determined the antibiotic resistance of the most frequently isolated bacterial strain (Streptococcus pneumoniae) found in these children. METHODS: This was a prospective study of 157 children with AOM aged from 6 months to 7 years admitted due to unsuccessful oral antibiotic treatment. All children underwent a myringotomy, and samples of the middle ear fluid were collected for bacteriological examination. RESULTS: Positive bacterial cultures were obtained in 104 patients (66.2%), with Streptococcus pneumoniae (39.69%), Haemophilus influenzae (16.03%) Staphylococcus aureus (16.03%), Staphylococcus haemolyticus (6.9%) and Streptococcus pyogenes (5.34%) found most frequently. The majority (65.4%) of S. pneumoniae strains were penicillin-intermediate-resistant or penicillin-resistant, and 67.2% strains of S. pneumoniae were multidrug-resistant. CONCLUSIONS: We identified S. pneumoniae as the most frequently isolated pathogen from the middle ear in children with AOM treatment failure and determined that the majority of strains were antibiotic-resistant. We propose that the microbiological identification of bacterial strains and their degree of antibiotic resistance should be performed prior to therapy in order to choose the most appropriate antibiotic therapy for children with AOM treatment failure.


Subject(s)
Drug Resistance, Multiple, Bacterial , Haemophilus Infections/drug therapy , Haemophilus influenzae/isolation & purification , Otitis Media with Effusion/drug therapy , Pneumococcal Infections/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus haemolyticus/isolation & purification , Streptococcus pneumoniae/drug effects , Streptococcus pyogenes/isolation & purification , Acute Disease , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Haemophilus Infections/complications , Humans , Infant , Male , Microbial Sensitivity Tests , Middle Ear Ventilation , Otitis Media with Effusion/microbiology , Otitis Media with Effusion/surgery , Penicillin Resistance , Pneumococcal Infections/complications , Prospective Studies , Staphylococcal Infections/complications , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/isolation & purification , Treatment Failure
6.
Undersea Hyperb Med ; 41(1): 51-7, 2014.
Article in English | MEDLINE | ID: mdl-24649717

ABSTRACT

INTRODUCTION: We report a case of a previously healthy adult with flulike symptoms who precipitously declined due to pneumococcal sepsis complicated by disseminated intravascular coagulation (DIC) and purpura fulminans (PF). After one week of care, including ventilation support and hemodialysis, the patient was stable enough for hyperbaric oxygen (HBO2) in an attempt to salvage his threatened extremities. HBO2 resulted in reduction of ischemic tissue and demarcation of blackened tissue to the distal digits. We feel that much at-risk tissue has been spared by HBO2 as an adjunctive therapy. METHODS: Literature on the use of hyperbaric oxygen for purpura fulminans was reviewed for precipitating issues, time to treatment, protocol, other adjuncts and outcomes. RESULTS: Fifteen papers were identified representing 19 cases of PF treated with HBO2. No controlled studies exist. HBO2 was believed to be of value in most cases; the improvement was associated with timeliness and aggressiveness of initiating HBO2. CONCLUSIONS: PF is a fulminant disorder with high mortality and morbidity. Hyperbaric oxygen appears to be useful for the management of PF complications, imposing minimal side effects or complications. Aggressive therapy should be started as soon as it is safe to transfer the patient to a facility for HBO2 treatments.


Subject(s)
Hyperbaric Oxygenation/methods , Purpura Fulminans/therapy , Adult , Combined Modality Therapy , Disseminated Intravascular Coagulation/complications , Humans , Hyperbaric Oxygenation/adverse effects , Male , Pneumococcal Infections/complications , Purpura Fulminans/complications , Purpura Fulminans/pathology , Respiratory Tract Infections/complications , Treatment Outcome
7.
Expert Opin Pharmacother ; 14(1): 65-77, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23256539

ABSTRACT

INTRODUCTION: The management of pneumococcal diseases still places a significant burden on medical and economic resources. The subjects at greatest risk of pneumococcal infections are children. AREAS COVERED: The aim of this review is to analyse the best current therapeutic approach to pneumococcal resistance, taking into account the level of susceptibility of Streptococcus pneumoniae, and the pharmacokinetics and pharmacodynamics of different antibiotics in the various pneumococcal diseases. EXPERT OPINION: Antibiotic treatment of a number of pneumococcal diseases remains difficult or impossible due to the presence of strains resistant to commonly used antibiotics. In children the problem is significantly more important than in adults due to the reduced number of licenced drugs for subjects in the first years of life. The new conjugate pneumococcal vaccines containing 10 (PCV10) and 13 serotypes (PCV13), which include most of the recently emerging strains, might reduce the incidence of pneumococcal infections and the circulation of resistant pathogens. However, it is likely that optimal results will only be reached after the development of effective vaccines based on conserved proteins that are capable of preventing all pneumococcal infections, regardless of the serotype of the causative organism.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Microbial/drug effects , Pneumococcal Infections/drug therapy , Anti-Bacterial Agents/pharmacokinetics , Bacteremia/drug therapy , Bacteremia/etiology , Child , Humans , Meningitis/drug therapy , Meningitis/etiology , Microbial Sensitivity Tests , Pneumococcal Infections/complications , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/immunology , Sepsis/drug therapy , Sepsis/etiology , Streptococcus pneumoniae/drug effects , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunology
8.
Audiol Neurootol ; 13(1): 65-70, 2008.
Article in English | MEDLINE | ID: mdl-17890859

ABSTRACT

Streptococcus pneumoniae can induce local and systemic diseases such as meningitis, otitis media, and pneumonia. One third of these meningitis cases can be associated with irreversible sensorineural hearing loss whose mechanisms likely involves the exotoxin pneumolysin (PLY) that irreversibly damages cochlear hair cells (HCs). In the respiratory system and in neuron it has been demonstrated that zinc deficiency increases severity and mortality of such infections in animal models and in children. Moreover, zinc supplementation can decrease the severity of pneumococcal respiratory infections. The aim of our study was to assess the potential protective effect of zinc against PLY toxicity on HCs in culture. Our results showed that in the presence of zinc at concentration as low as 1 microM, the toxicity of PLY was largely reduced by about 50% for both inner and outer HCs. At 300 microM of zinc, protection significantly increased with 62 and 55.2% for IHCs and OHCs, respectively. Our results suggest that the protective effect of zinc is likely due to an inhibition of the toxin incorporation and aggregation into the plasma membrane, thus preventing calcium influx through the toxin pores. Our findings raise the possibility that treatments with zinc may help to prevent debilitating otological sequelae from pneumococcal infection.


Subject(s)
Hair Cells, Auditory/drug effects , Hair Cells, Auditory/pathology , Streptolysins/toxicity , Trace Elements/pharmacology , Zinc/pharmacology , Animals , Bacterial Proteins/toxicity , Dose-Response Relationship, Drug , Drug Interactions , Hearing Loss/microbiology , Hearing Loss/prevention & control , Organ Culture Techniques , Pneumococcal Infections/complications , Rats , Rats, Wistar , Streptococcus pneumoniae
9.
Rev. chil. infectol ; 23(3): 243-246, sept. 2006. ilus
Article in Spanish | LILACS | ID: lil-433434

ABSTRACT

Streptococcus pneumoniae es el principal agente de infección bacteriana invasora en niños; sin embargo, es extremadamente infrecuente como causa de endocarditis. Esta entidad clínica se manifiesta generalmente como una enfermedad aguda y grave con alta mortalidad, que requiere tratamiento médico-quirúrgico precoz, afectando con mayor frecuencia la válvula mitral. Presentamos el caso de una niña de 6 años 4 meses, de extrema ruralidad, que presentó endocarditis infecciosa (EI) de válvula mitral asociada a meningitis, aislándose en hemocultivos S. pneumoniae resistente a penicilina y se discute las estrategias terapéuticas...


Subject(s)
Humans , Female , Child , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/drug therapy , Pneumococcal Infections/complications , Streptococcus pneumoniae/isolation & purification , Mitral Valve/microbiology , Anti-Bacterial Agents/therapeutic use , Clinical Evolution , Endocarditis, Bacterial/surgery , Penicillin Resistance , Treatment Outcome , Mitral Valve/surgery
10.
Rev. chil. infectol ; 22(4): 361-367, dic. 2005. ilus, tab
Article in Spanish | LILACS | ID: lil-427726

ABSTRACT

La endocarditis causada por Streptococcus pneumoniae es una patología muy poco frecuente en niños, correspondiendo sólo a 3 - 7 por ciento de los casos. Sin embargo, su importancia radica en que se puede presentar de forma muy agresiva, con complicaciones como destrucción valvular y abscesos, y con una mortalidad reportada hasta 61 por ciento, de no mediar tratamiento antimicrobiano precoz y muchas veces cardiocirugía. En más del 50 por ciento se puede asociar a otros focos infecciosos, como meningitis, neumonía, sinusitis o mastoiditis. Se describe el caso de una lactante de 10 meses que presentó una meningitis asociada a endocarditis debidas a S. pneumoniae, con grave compromiso cardíaco, y que requirió reemplazo valvular. Se realizó una revisión de la literatura médica acerca de endocarditis por S. pneumoniae en niños.


Subject(s)
Humans , Female , Infant , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/therapy , Pneumococcal Infections/complications , Pneumococcal Infections/therapy , Meningitis/complications , Anti-Bacterial Agents/therapeutic use , Clinical Evolution , Pulmonary Edema/microbiology , Heart Valve Prosthesis , Aortic Valve Insufficiency/surgery , Aortic Valve Insufficiency/microbiology , Signs and Symptoms , Treatment Outcome
11.
J Antimicrob Chemother ; 56(4): 732-7, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16150863

ABSTRACT

OBJECTIVES: To compare the in vitro and in vivo activity of penicillin, cefotaxime and ceftriaxone, using three strains of Streptococcus pneumoniae with different susceptibilities to penicillin (MICs of 0.015, 0.25 and 2 mg/L, respectively). METHODS: Time-kill curves and an experimental model of endocarditis in rabbits. RESULTS: Penicillin was efficacious in clearing bacteria from vegetations and blood irrespective of whether infections were caused by penicillin-susceptible or penicillin-resistant strains (P < 0.01 with respect to control groups). The same efficacy was shown with cefotaxime and ceftriaxone. Comparing the results of the in vivo model with those obtained in time-kill curves, penicillin showed the best results. CONCLUSIONS: These results confirm that penicillin is efficacious in the treatment of pneumococcal infections, including those produced by strains with MICs < or = 2 mg/L (with the exception of pneumococcal meningitis). These results also suggest that the breakpoints to define susceptibility and resistance of S. pneumoniae to penicillin must be reviewed, as has been done with amoxicillin and third-generation cephalosporins.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Penicillin Resistance , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/drug effects , beta-Lactams/therapeutic use , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Cefotaxime/blood , Cefotaxime/pharmacokinetics , Cefotaxime/pharmacology , Cefotaxime/therapeutic use , Ceftriaxone/blood , Ceftriaxone/pharmacokinetics , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Endocarditis, Bacterial/complications , Half-Life , Microbial Sensitivity Tests , Penicillins/blood , Penicillins/pharmacokinetics , Penicillins/pharmacology , Penicillins/therapeutic use , Pneumococcal Infections/complications , Pneumococcal Infections/microbiology , Rabbits , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/physiology , beta-Lactams/blood , beta-Lactams/pharmacokinetics , beta-Lactams/pharmacology
12.
Int J Antimicrob Agents ; 23(1): 25-31, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14732310

ABSTRACT

A gerbil model of acute otitis media induced by Streptococcus pneumoniae plus Haemophilus influenzae was used to assess the efficacy of amoxicillin/clavulanic acid (A/C) (1.5/0.3, 2.5/0.5 and 10/2 mg/kg) and erythromycin (2.5, 10, 20 and 50 mg/kg) with or without acetaminophen. The amoxicillin/clavulanic acid MIC was 1/0.5 mg/l for both organisms and the erythromycin MICs were 0.12 and 4 mg/l for S. pneumoniae and H. influenzae, respectively. The organisms were inoculated directly into the middle ear (ME) and antibiotic treatment started 2 h post-inoculation and continued at 8h intervals for three doses. Acetaminophen was administered at 50 mg/kg. Samples for bacterial counting were obtained from the ME on day 2. Amoxicillin/clavulanic acid peri-MIC concentrations in ME were effective in eradicating both organisms. Despite the inflammation induced by S. pneumoniae, erythromycin did not eradicate H. influenzae at ME concentrations (2.4 mg/l for erythromycin 50 mg/kg) higher than those obtained in humans but lower than the MIC.


Subject(s)
Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Erythromycin/therapeutic use , Haemophilus Infections/drug therapy , Otitis Media/drug therapy , Pneumococcal Infections/drug therapy , Animals , Disease Models, Animal , Drug Therapy, Combination , Gerbillinae , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Microbial Sensitivity Tests , Otitis Media/metabolism , Otitis Media/microbiology , Pneumococcal Infections/complications , Pneumococcal Infections/microbiology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification
13.
Eur J Clin Microbiol Infect Dis ; 21(5): 389-92, 2002 May.
Article in English | MEDLINE | ID: mdl-12072925

ABSTRACT

Presented here is the case of a 63-year-old patient with a Streptococcus pneumoniae-infected aneurysm extending from a persistent lobar pneumonia of the left lung into the thoracic aorta. The patient was successfully treated with surgery and high-dose penicillin, and he remained well at 6-month follow-up. A review of the English-language literature over the past 25 years revealed 22 cases of mycotic or infected aortic aneurysms due to Streptococcus pneumoniae; however, none of these cases resulted in a positive outcome for the patient. The characteristics of these cases are discussed.


Subject(s)
Aneurysm, Infected/complications , Aneurysm, Infected/microbiology , Pneumococcal Infections/complications , Pneumococcal Infections/microbiology , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/microbiology , Streptococcus pneumoniae , Aged , Aneurysm, Infected/drug therapy , Aorta, Abdominal/microbiology , Aorta, Abdominal/pathology , Humans , Male , Penicillin G/therapeutic use , Penicillins/therapeutic use , Pneumococcal Infections/drug therapy , Pneumonia, Bacterial/drug therapy , Streptococcus pneumoniae/isolation & purification
14.
Clin Infect Dis ; 35(2): 130-9, 2002 Jul 15.
Article in English | MEDLINE | ID: mdl-12087518

ABSTRACT

We performed a clinical study of pneumococcal endocarditis (PE) in adults at 15 major Spanish hospitals during a 21-year period (1978-1998). During this time, 63 patients had PE due to Streptococcus pneumoniae diagnosed. Of the 63 isolates recovered from these patients, 24 (38%) and 6 (10%) showed resistance to penicillin (minimum inhibitory concentration [MIC], 0.1-4 microg/mL) and cefotaxime (MIC, 1 microg/mL), respectively. Twenty-two (35%) of the patients died. Left-side heart failure, but not penicillin resistance, was independently associated with a higher risk of death (odds ratio, 1.33; 95% confidence interval, 1.04-1.71; P=.026). Patients without meningitis who had PE due to penicillin-resistant S. pneumoniae could be treated with high-dose penicillin or a third-generation cephalosporin if the MIC for penicillin was < or =1 microg/mL. For patients with concurrent meningitis, high doses of cefotaxime could be used if the MIC for cefotaxime was < or =1 microg/mL. Early recognition of heart failure and surgery may help to decrease mortality.


Subject(s)
Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Penicillin Resistance , Penicillins/metabolism , Pneumococcal Infections/diagnosis , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification , Adult , Aged , Cefotaxime/administration & dosage , Cefotaxime/metabolism , Cefotaxime/therapeutic use , Cephalosporins/administration & dosage , Cephalosporins/metabolism , Cephalosporins/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/epidemiology , Female , Heart Failure/etiology , Heart Failure/mortality , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Penicillins/administration & dosage , Penicillins/therapeutic use , Pneumococcal Infections/complications , Pneumococcal Infections/epidemiology , Prognosis , Prospective Studies , Spain/epidemiology , Treatment Outcome , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/surgery
15.
Pediátrika (Madr.) ; 20(9): 341-345, oct. 2000. tab
Article in Es | IBECS | ID: ibc-13169

ABSTRACT

La celulitis orbitaria comprende dos patologías bien diferenciadas desde un punto de vista anatomoclínico: la forma preseptal y la postseptal. Constituye una enfermedad infecciosa relativamente frecuente en la edad pediátrica que, normalmente, es secundaria a sinusitis. Presentamos una revisión de esta patología haciendo especial hincapié en el cambio etiológico acontecido en la última década tras la vacunación sistemática contra Haemophilus influenzae tipo B. (AU)


Subject(s)
Female , Child, Preschool , Male , Humans , Cellulite/diagnosis , Haemophilus influenzae/immunology , Paranasal Sinuses/pathology , Bites and Stings/complications , Bites and Stings/diagnosis , Bites and Stings/etiology , Streptococcus/isolation & purification , Streptococcus/pathogenicity , Thrombophlebitis/complications , Thrombophlebitis/diagnosis , Thrombophlebitis/therapy , Cavernous Sinus/pathology , Exophthalmos/complications , Exophthalmos/diagnosis , Exophthalmos/therapy , Fever/complications , Fever/diagnosis , Fever/therapy , Pain/complications , Pain/diagnosis , Pain/therapy , Tomography, X-Ray Computed/methods , Sinusitis/diagnosis , Sinusitis/therapy , Sinusitis/complications , Sinusitis , Clindamycin/therapeutic use , Nasal Septum/pathology , Nasal Septum , Magnetic Resonance Spectroscopy/methods , Anti-Bacterial Agents/therapeutic use , Microbial Sensitivity Tests , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/pathogenicity , Conjunctivitis/complications , Conjunctivitis/diagnosis , Conjunctivitis/therapy , Pneumococcal Infections/complications , Pneumococcal Infections/diagnosis , Pneumococcal Infections/therapy , Moraxella catarrhalis/isolation & purification , Moraxella catarrhalis/pathogenicity , Cellulite/epidemiology , Cellulite/pathology , Cellulite/classification , 24959 , Central Nervous System/pathology , Meningitis/complications , Meningitis/diagnosis , Meningitis/therapy , Prognosis , Diagnosis, Differential , Sepsis/complications , Sepsis/diagnosis , Sepsis/mortality , Sepsis/therapy
16.
Eur J Gastroenterol Hepatol ; 10(4): 353-4, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9855054

ABSTRACT

A 78-year-old lady initially presented with painful hips, low back pain, lethargy and weight loss. She had a past history of osteomalacia. Investigations revealed evidence of malabsorption and jejunal biopsy revealed sub-total villous atrophy in keeping with coeliac disease. Peripheral blood film was within normal limits. She responded well clinically to a gluten-free diet and calcium and vitamin D supplementation. Four years after the initial diagnosis she presented acutely with vomiting, pleuritic chest pain, pyrexia and bronchospasm. Blood cultures confirmed the presence of Streptococcus pneumoniae and she was treated appropriately with ampicillin. Despite this she died shortly after admission. It is recognized that blood film examination alone cannot exclude hyposplenism complicating coeliac disease and it is presumed that this was the reason for the development of fatal pneumococcal septicaemia in this patient. Prophylactic vaccination may be appropriate in hyposplenism secondary to coeliac disease.


Subject(s)
Bacteremia/complications , Celiac Disease/complications , Pneumococcal Infections/complications , Splenic Diseases/complications , Aged , Fatal Outcome , Female , Humans
18.
Am J Pediatr Hematol Oncol ; 7(3): 235-9, 1985.
Article in English | MEDLINE | ID: mdl-3907390

ABSTRACT

The Jamaican sickle cell cohort study, based on neonatal diagnosis of all cases of sickle cell disease among 100,000 consecutive births, has identified acute splenic sequestration (ASS) and pneumococcal disease as the most important complications in early life. The etiology of ASS is unknown and prophylaxis is therefore not possible. For first attacks, attention has been directed to parental education to achieve earlier diagnosis. Recurrent attacks may be prevented by prophylactic splenectomy. A controlled trial on the prevention of pneumococcal disease has indicated many pneumococcal septicemias in children given the 14 valent pneumococcal vaccine between the ages of 6 months and 3 years. No pneumococcal isolations occurred during the same period in children given monthly long-acting prophylactic penicillin. A controlled trial of folate supplementation for 1 year in children aged 6 months to 4 years indicated no difference between control and treatment groups in hemoglobin levels or weight and height velocity. The MCV was 4 fl less in the supplemented group. A controlled trial of feeder vessel photocoagulation in the therapy of proliferative retinopathy indicated significantly less vitreous hemorrhage in treated patients, but choroidal neovascularisation was a common complication of xenon arc therapy, and retinal tears commonly followed the use of the Argon laser. A new trial of scatter therapy is in progress.


Subject(s)
Anemia, Sickle Cell/therapy , Pneumococcal Infections/complications , Splenic Diseases/complications , Acute Disease , Anemia, Sickle Cell/complications , Bacterial Vaccines , Body Weight , Child , Child, Preschool , Clinical Trials as Topic , Double-Blind Method , Folic Acid/therapeutic use , Food, Fortified , Haemophilus influenzae , Hemoglobins/analysis , Humans , Infant , Jamaica , Mass Screening , Penicillins/therapeutic use , Pneumococcal Infections/mortality , Pneumococcal Infections/prevention & control , Prospective Studies , Random Allocation , Retinal Diseases/complications , Retinal Diseases/prevention & control , Splenectomy , Splenic Diseases/mortality , Splenic Diseases/prevention & control
19.
Am J Pediatr Hematol Oncol ; 7(3): 235-9, 1985.
Article in English | MedCarib | ID: med-15907

ABSTRACT

The Jamaican sickle cell cohort study, based on neonatal diagnosis of all cases of sickle cell disease among 100 000 consecutive births, has identified acute splenic sequestration (ASS) and pneumoccocal disease as the most important complications in early life. The etiology of ASS is unknown and prophylaxis is therefore not possible. For first attacks, attention has been directed to parental education to achieve earlier diagnosis. Recurrent attacks may be prevented by prophylactic splenectomy. A controlled trial on the prevention of pneumococcal disease has indicated many pneumococcal septicemias in children given the 14 valent pneumococcal vaccine between the ages of 6 months and 3 years. No pneumococcal isolations occurred during the same period in children given monthly long-acting prophylactic penicillin. A controlled trial of foliate supplementation for 1 year in children aged 6 months to 4 years indicated no difference between control and treatment groups in hemoglobin levels or weight and height velocity. The MVC was 4 fl less in the supplemented group. A controlled trial of feeder vessel photocoagulation in the therapy of proliferative retionpathy indicated significantly less vitreous hemorrhage in treated patients but choroidal neovascularization was a common complication of xenon arc therapy and retinal tears commonly followed the use of Argon laser. A new trial of scatter therapy is in progress. (AU)


Subject(s)
Humans , Infant , Child, Preschool , Child , Anemia, Sickle Cell/therapy , Pneumococcal Infections/complications , Splenic Diseases/complications , Acute Disease , Anemia, Sickle Cell/therapy , Bacterial Vaccines , Body Weight , Clinical Trials as Topic , Double-Blind Method , Folic Acid/therapeutic use , Food, Fortified , Haemophilus influenzae , Hemoglobins/analysis , Jamaica , Mass Screening , Penicillins/therapeutic use , Pneumococcal Infections/mortality , Pneumococcal Infections/prevention & control , Prospective Studies , Random Allocation , Retinal Diseases/complications , Retinal Diseases/prevention & control , Splenectomy , Splenic Diseases/mortality , Splenic Diseases/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL